Sign In
Buy MNMD
$20.69
+0 (+0%)
At Close: Jun 18, 2026
The stock of psychedelics company Mind Medicine Inc. MNMD, +4.82% rose 4% Friday, after the company's Swiss research partners reported positive results from a Phase 2 trial of LSD as a treatment for m
MindMed shares spike on positive results from LSD trial
10:49am, Friday, 14'th Apr 2023
MindMed (NASDAQ:MNMD, NEO:MMED)'s shares moved higher after the biopharmaceutical company released positive topline data from its collaborators' trial evaluating lysergide (LSD) in the treatment of ma
Why Is Mind Medicine (MNMD) Stock Up 26% Today?
09:32am, Friday, 14'th Apr 2023
Mind Medicine (NASDAQ: MNMD ) stock is on the rise Friday after releasing positive results from a Phase 2 clinical trial. That clinical trial saw the company testing the effectiveness of treating MDD�
The 7 Most Promising Psychedelic Stocks to Buy in February
02:30pm, Sunday, 05'th Feb 2023
Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine. Several pharmaceutical companies are now investigating their potential therapeutic value.
Psychedelic Sunday: Competitive Strategies
11:45am, Sunday, 15'th Jan 2023
Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage?
Scrutinizing Psychedelic Stocks
11:30am, Sunday, 08'th Jan 2023
What makes a psychedelic company compelling? Analyst Alex Carchidi has a background in biotech and focuses on long-term growth and risk management.
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
09:49pm, Tuesday, 06'th Dec 2022
Atai, Biogen, and Sage are working to develop new treatments for mental illness.
MindMed price target lowered by Canaccord analysts after Phase 2a US clinical trial shelved
11:55am, Monday, 21'st Nov 2022
Mind Medicine (MindMed (NASDAQ:MNMD, NEO:MMED)) Inc has earned a repeat ‘Speculative Buy' rating with a lowered price target of US$18 from US$22 per share from Canaccord Genuity (TSX:CF, LSE:CF) ana
Mind Medicine (MindMed), Inc. (MNMD) Q3 2022 Earnings Call Transcript
12:21pm, Thursday, 10'th Nov 2022
Mind Medicine (MindMed), Inc. (NASDAQ:MNMD ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Robert Barrow - CEO & Director Schond Greenway - CFO Daniel Karlin - Chi
7 Speculative Penny Stocks Under $3 That Deserve Your Attention in Nov.
02:49pm, Friday, 28'th Oct 2022
Risk is part of investing. Even the most mature, well-established firms and stocks run the risk of declining to zero.
Mind Medicine (MNMD) to Report Q3 Earnings: What's in Store?
05:18pm, Wednesday, 26'th Oct 2022
Mind Medicine MindMed (MNMD) is expected to provide an update on its pipeline candidates in its third-quarter earnings.
10 Top Penny Stocks To Buy According To Wall Street Analysts In 2022
02:12pm, Wednesday, 19'th Oct 2022
Penny stocks to buy according to analysts in 2022. The post 10 Top Penny Stocks To Buy According To Wall Street Analysts In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | Pe
Why Mind Medicine Zoomed 8% Higher on Tuesday
05:33pm, Tuesday, 18'th Oct 2022
The support for legalizing drugs -- such as those being studied by the company -- grows with a U.S. senator's tweet.
7 Penny Stocks To Buy According To Top Wall Street Analysts
02:52pm, Tuesday, 18'th Oct 2022
Penny stocks to buy according to analysts in 2022. The post 7 Penny Stocks To Buy According To Top Wall Street Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks
These Were The Five Best And Worst Performing Healthcare Stocks In September 2022
07:41pm, Monday, 17'th Oct 2022
September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.
